Sabby Management buys $30,150,649 stake in Regeneron Pharmaceuticals Inc (REGN)

Regeneron Pharmaceuticals Inc (REGN) : Sabby Management scooped up 32,498 additional shares in Regeneron Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 71,525 shares of Regeneron Pharmaceuticals Inc which is valued at $30,150,649.Regeneron Pharmaceuticals Inc makes up approximately 9.94% of Sabby Management’s portfolio.

Other Hedge Funds, Including , Voloridge Investment Management sold out all of its stake in REGN during the most recent quarter. The investment firm sold 59,746 shares of REGN which is valued $25,185,329.Blackrock Advisors boosted its stake in REGN in the latest quarter, The investment management firm added 227,998 additional shares and now holds a total of 418,943 shares of Regeneron Pharmaceuticals Inc which is valued at $176,601,232. Regeneron Pharmaceuticals Inc makes up approx 0.18% of Blackrock Advisors’s portfolio. Wrapmanager Inc added REGN to its portfolio by purchasing 637 company shares during the most recent quarter which is valued at $268,521. Regeneron Pharmaceuticals Inc makes up approx 0.11% of Wrapmanager Inc’s portfolio.New Century Investment Management Inc reduced its stake in REGN by selling 122 shares or 4.63% in the most recent quarter. The Hedge Fund company now holds 2,511 shares of REGN which is valued at $982,655. Regeneron Pharmaceuticals Inc makes up approx 0.50% of New Century Investment Management Inc’s portfolio.

Regeneron Pharmaceuticals Inc opened for trading at $394.75 and hit $394.75 on the upside on Thursday, eventually ending the session at $393.4, with a gain of 0.22% or 0.85 points. The heightened volatility saw the trading volume jump to 4,79,344 shares. Company has a market cap of $41,423 M.

On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.

Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Shares were Downgraded by Robert W. Baird on Aug 5, 2016 to ” Neutral” and Lowered the Price Target to $ 448 from a previous price target of $505 .Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.

Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *